Literature DB >> 2415593

Human interleukin 1 is a cytocidal factor for several tumor cell lines.

K Onozaki, K Matsushima, B B Aggarwal, J J Oppenheim.   

Abstract

Highly purified interleukin 1 (IL 1) obtained from stimulated human monocytes appeared to be growth inhibitory and cytocidal for a human melanoma cell line, A375. Although IL 1 did not have an immediate cytolytic effect, with time in culture the growth of the target cells was irreversibly inhibited. The cells eventually lysed and decreased markedly in number; the IL 1 effect can therefore be said to be cytocidal. IL 1 activity could not be separated from the cytocidal activity by a variety of chromatography procedures by using conventional and high-performance liquid chromatography (HPLC). The A375 melanoma cell line was also sensitive to another human cytokine alpha-lymphotoxin (alpha-LT) derived from a human B cell line. IL 1 also appeared to be partially growth inhibitory and cytocidal for a LT-sensitive mouse fibroblast cell line, L929; but not for LT-resistant cells, including a subline of L929; a human epithelial carcinoma cell line, HeLa; a human osteosarcoma cell line, HOS; and a mouse SV40-transformed kidney cell line, TU5. However, the LT-sensitive mouse fibroblast cell line, L-M, was resistant to IL 1. Therefore, the cytocidal activity of IL 1 only partially overlapped the target cell selectivity of alpha-LT. Although natural IFN-alpha and recombinant IFN-beta were appreciably growth inhibitory for the A375 cell line, natural and recombinant IFN-alpha and recombinant IFN-beta and IFN-gamma exhibited little cytocidal activity. Purified IL 1 did not have any antiviral activity, and conversely, IFN and alpha-LT were not co-mitogenic for thymocytes. Furthermore, by ELISA and radioimmunoassays, antibodies against human alpha-LT, tumor necrosis factor, and IFN-gamma did not react with IL 1, indicating that IL 1 is antigenically distinct from these other cytokines. These in vitro results suggest that IL 1 may play a role in host defense against some tumors as a cytocidal factor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2415593

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  85 in total

1.  Differential effects of human blood monocytes on the growth of human tumour cell lines in vitro.

Authors:  H J Parry; R C Rees
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.

Authors:  J Tanner; G Tosato
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 3.  Interleukins. Clinical pharmacology and therapeutic use.

Authors:  W E Aulitzky; M Schuler; C Peschel; C Huber
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

Review 4.  The NLRP3 inflammasome in health and disease: the good, the bad and the ugly.

Authors:  P Menu; J E Vince
Journal:  Clin Exp Immunol       Date:  2011-07-15       Impact factor: 4.330

5.  Lysing of fresh human tumor by a cytotoxic factor derived from autologous large granular lymphocytes independently of other known cytokines.

Authors:  A Uchida; T Fujimoto; Y Mizutani
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Effect of insulin on the production and action of interleukin 1.

Authors:  Z H Feng; Y Luo; R D Wang; Z C Chen
Journal:  J Tongji Med Univ       Date:  1988

7.  Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF.

Authors:  Y Ichinose; J Y Tsao; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution.

Authors:  Janice P Dutcher; Donna Neuberg; Michael B Atkins; William J Tester; Scott Wadler; James A Stewart; Abraham Chachoua; Lynn M Schuchter
Journal:  J Interferon Cytokine Res       Date:  2014-01-16       Impact factor: 2.607

9.  Prolonged exposure of rat aorta to low levels of endotoxin in vitro results in impaired contractility. Association with vascular cytokine release.

Authors:  T M McKenna
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

10.  Preventive effects of interleukin 1 beta for ACNU-induced myelosuppression in malignant brain tumors: the experimental and preliminary clinical studies.

Authors:  S Tanaka; S Tabuchi; K Watanabe; H Takigawa; K Akatsuka; H Numata; Y Hokama; T Hori
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.